Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
iwCLL 2021
#COSTEM23 | Riccardo Saccardi of @AOUCareggi gives an insight into the impact various conditioning regimens have on the outcomes of patients with autoimmune diseases.
Watch here:
👉 👈
#HemOnc @COSTEMCongress
The impact of conditioning regimens on the outcomes of patients with autoimmune diseases
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses the impact of various conditioning regimens...
ow.ly
Have you seen our NEW feature: 'Spotlight on Lower-risk #MDS'? 🗞️🩸
It is the first in a practical #educational series💡🎥
Hear from leading #MDS experts: @UwePlatzbecker, @sanamloghavi, Robert Hasserjian & Valeria Santini
Take a look 👉
#HemOnc #LRMDS
Spotlight On Lower-risk MDS
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
www.vjhemonc.com
Managing the shift from pediatric to adult SCD care @VJHemOnc
🎥 Varsha Gandhi of @MDAndersonNews speaks on a strategy for curing CLL one clone at a time.
Click here to find out more:
👉👈
#CLLsm #Leukemia #Leusm #iwCLL2023 @iwcll
A strategy for curing CLL, one clone at a time
Varsha Gandhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the key points from a ...
ow.ly
Should #CART be advanced into earlier lines of myeloma treatment? Michel Delforge (@KU_Leuven) explores this question, shedding light on the ongoing CARTITUDE-5 & CARTITUDE-6 trials:
👉
#CTSM #TrialUpdate #ImmunoOnc #MMsm #IMS23 @myeloma_society
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses whether CAR-T cells might be integrated int...
ow.ly
iwCLL 2021
#COSTEM23 | Riccardo Saccardi of @AOUCareggi gives an insight into the impact various conditioning regimens have on the outcomes of patients with autoimmune diseases.
Watch here:
👉 👈
#HemOnc @COSTEMCongress
The impact of conditioning regimens on the outcomes of patients with autoimmune diseases
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses the impact of various conditioning regimens...
ow.ly
Have you seen our NEW feature: 'Spotlight on Lower-risk #MDS'? 🗞️🩸
It is the first in a practical #educational series💡🎥
Hear from leading #MDS experts: @UwePlatzbecker, @sanamloghavi, Robert Hasserjian & Valeria Santini
Take a look 👉
#HemOnc #LRMDS
Spotlight On Lower-risk MDS
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
www.vjhemonc.com
Managing the shift from pediatric to adult SCD care @VJHemOnc
🎥 Varsha Gandhi of @MDAndersonNews speaks on a strategy for curing CLL one clone at a time.
Click here to find out more:
👉👈
#CLLsm #Leukemia #Leusm #iwCLL2023 @iwcll
A strategy for curing CLL, one clone at a time
Varsha Gandhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the key points from a ...
ow.ly
Should #CART be advanced into earlier lines of myeloma treatment? Michel Delforge (@KU_Leuven) explores this question, shedding light on the ongoing CARTITUDE-5 & CARTITUDE-6 trials:
👉
#CTSM #TrialUpdate #ImmunoOnc #MMsm #IMS23 @myeloma_society
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses whether CAR-T cells might be integrated int...
ow.ly
